Global Diabetes Non-Profit Beyond Type 1 Celebrates World Diabetes Day With Guiness World Record Attempt

Beyond Type 1 is celebrating Sir Frederick Banting’s 127th birthday on Wednesday, November 14th with a coalition of almost 50 organizations attempting to break the Guinness World Record for most contributions to an e-greeting card.

Diabeloop Obtains CE Marking for DBLG1

Diabeloop, a French medical technology company that specializes in creating accessible innovations for the Type 1 diabetes community, has obtained CE marking for its DBLG1 System.

Abbott’s FreeStyle Libre Gains CE Mark In Europe

Earlier this month, Abbott announced that its FreeStyle Libre 2 system had secured CE Mark clearance in the European Union. The system will be launched on a rolling basis throughout Europe, starting in the coming weeks, according to the company.

Research Shows Fridges Might Be Destroying Insulin

A 16-month study has shown that 79% of insulin is kept at temperatures outside of the recommended range. Insulin stored in the fridge is at a much higher risk.

$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes

Today, ViaCyte and W.L. Gore & Associates announced a $10 million investment by Gore into ViaCyte. This is the second multimillion dollar investment by Gore, following a first in 2017.

CRISPR Therapeutics and ViaCyte’s Strategic Collaboration to Develop Gene‐Edited Stem Cell‐Derived Therapy for Diabetes

Yesterday, CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company that develops transformative gene‐based medicines for serious diseases, and ViaCyte, Inc., a regenerative medicine company, announced their collaboration.

T1D Care in the Wake of Typhoon Mangkhut

Typhoon Mangkhut has slammed the Philippines, Hong Kong and continues a destruction path across Southern China.

Immunotherapy for Type 1 Diabetes

“For a long time, everybody thought that Type 1 would be cured by immunosuppression,” said The Faustman Lab’s Dr. Denise L. Faustman, M.D., Ph.D., but the past 30 years of discovery “have proven that immunostimulation is what’s needed.”

Can an Antihypertensive Drug Preserve Beta Cell Function in Early Type 1 diabetes?

A study published this week in Nature reported that an FDA-approved antihypertensive drug, verapamil, might slow the progression of beta cell destruction at Type 1 diabetes onset.

Eversense from Senseonics – The First Implantable CGM

Could implantable technology be the future of continuous glucose monitoring? Meet the Eversense CGM, made by device company Senseonics.

FDA Approves Basal-IQ Predictive Low Suspend for the t:slim X2 Pump from Tandem

Tandem announces FDA approval of the Basal-IQ™ technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events for the t:slim X2™ Insulin Pump.

Breaking News From #2018ADA

The most important and groundbreaking news coming out of the 78th Scientific Sessions, updated regularly over the course of the conference

Omnipod DASH System from Insulet Receives FDA Clearance

Omnipod DASH(TM) Insulin Management System has received 510(K) clearance from the FDA. This clearance allows Insulet to commercialize this product in the United States, though Insulet has announced that it will begin roll-out through a limited market launch. Full market release is estimated to begin in early 2019 in the United States.

Are You A DIABADASS? – The Diabadass Tour

Cassidy Robinson and Erik Douds are hitting the road again - and want to see you along the way! Find out what the Diabadass Tour is all about.

Cell Replacement and Type 1 Diabetes: Encellin’s Solution

Bay Area start-up Encellin is pursuing pancreatic cell replacement therapy in a more body-palatable form.